BMS Expands Oncology Portfolio with Eisai’s MORAb-202

By Neha Madhwani

Pharma Deals Review: Vol 2021 Issue 7 (Table of Contents)

Published: 28 Jul-2021

DOI: 10.3833/pdr.v2021.i7.2630     ISSN: 1756-7874

Section: Research & Development



Bristol Myers Squibb (BMS) has agreed to pay US$650 M upfront to access Eisai’s anti-folate receptor alpha (FRalpha) antibody, MORAb-202, which is currently in a Phase I clinical study in Japan and Phase I/II trials in the US...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details